Guardant Health price target lowered to $64 from $74 at Craig-Hallum

Craig-Hallum analyst Alexander Nowak lowered the firm’s price target on Guardant Health to $64 from $74 and keeps a Buy rating on the shares. The firm notes Guardant Health put up solid performance with Therapy Selection and ASP gains, continuing the strength seen in Q2. There was less sequential growth this quarter amid a catch-up in ESR1 the first half of 2023. But this quarter did demonstrate that the strength originally seen in Q2 is not a one-time event, Craig-Hallum says, adding that it might be seen as an inflection point.